Immuneering Q1 net loss $12.9M; reiterates FY2022 opex $55-60M; IMM-1-104 IND on track for Q3 2022

Immuneering Corp

2022-Q1 EPS reported -$0.49 revenue$183,698

Net loss $12.9M ($0.49/share) vs $6.2M ($1.26/share) in Q1 2021; R&D $9.1M, G&A $4.0M.
Cash $137.8M as of March 31, 2022; cash runway into Q3 2024.
IMM-1-104 IND filing expected Q3 2022; first patient enrollment Phase 1 expected Q4 2022.
IMM-6-415 IND filing expected 2023.
FY2022 GAAP opex guidance $55-60M including non-cash stock-based comp.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.